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The Effects of Low-Intensity Therapeutic Ultrasound
on Measurable Outcomes: A Critically Appraised Topic
Sarah Daniels, Gabriela Santiago, Jennifer Cuchna, and Bonnie Van Lunen
Clinical Scenario: Therapeutic ultrasound (US) is a popular modality among health care professionals and is used to treat a
variety of musculoskeletal conditions. A new technology has been established to allow for the miniaturization of the US unit.
Patients receive treatment with the device secured to them, eliminating the portability constraint of traditional US units. Early
studies suggest that this portable unit can deliver low-intensity acoustic energy achieving the same temperature increase and pain
relief that come from traditional US units, in a more versatile and patient-friendly manner. Clinical Question:What effects does
low-intensity therapeutic ultrasound (LITUS) have on measurable outcomes? Summary of Key Findings: The literature was
searched for level 4 evidence or higher that investigated the effectiveness of LITUS. The literature search produced 3 possible
studies related to the clinical question: 2 randomized controlled trials and 1 case series met the inclusion and exclusion criteria. Of
the included studies, 1 study investigated the effects of LITUS on tissue temperature, 2 studies investigated the effects of LITUS
on pain, and 1 study investigated LITUS effects on function. Clinical Bottom Line: The evidence supports the use of the LITUS
unit to increase tissue temperature, decrease pain, and increase function. Therefore, practitioners may consider the use of the
LITUS unit in patient populations over the use of the traditional high-intensity US treatment. Strength of Recommendation:
In accordance with the 2009 Centre for Evidence-Based Medicine levels of evidence, there is grade I (insufficient) evidence to
support the positive effects of the LITUS device for improving the following clinical outcomes: tissue temperature, decreasing
pain, and increasing function. The inconsistency in the measured outcomes across the 3 studies only allows for minimal support
of the LITUS device, warranting further research. Although clinical outcomes were different in each study, consistent evidence
ranging from 4 to 1B levels were found in the 3 included studies.
Keywords: temperature, pain, ultrasonic therapy
Clinical Scenario
Therapeutic ultrasound (US) is a popular modality among health
care professionals and is used to treat a variety of musculoskeletal
conditions.1 Throughout the past 70 years of clinical use,2 US has
been shown to be an effective way to decrease pain,2,3 increase
tissue temperature,4 and decrease tissue stiffness of trigger points,5
among other benefits. Treatment parameters with US are typically
high intensity and occur over a short period (minutes). The US
machine is large and stationary, forcing patients to be nonmobile
for the duration of their treatment. However, the new technology
established by Lewis et al3 has allowed for the miniaturization of
the US unit. After pilot testing and trial runs, a low-intensity
therapeutic ultrasound (LITUS) unit that fits easily into the palm
of a hand has been developed and is currently available.2 To use the
device, US coupling gel is applied directly to the skin over the
desired treatment area and the transducer is secured with adhesive
bandages. Patients receive treatment with the device secured to
them, eliminating the portability constraint of traditional US units.
Depending on the parameters chosen (refer to Table 2), the unit
may provide treatment for up to 5–6 consecutive hours without
needing to charge the unit battery.3 Early studies suggest that this
portable unit can deliver low-intensity acoustic energy over a
prolonged period (hours), as well as medium-intensity treatments
over a shorter period (minutes), achieving the same temperature
increase and pain relief that come from traditional US units, in a
more versatile and patient-friendly manner.3
Focused Clinical Question
What effects does LITUS have on measurable outcomes?
Summary of Search, Best Evidence
Appraised, and Key Findings
• The literature was searched for studies of level 4 evidence
or higher (based on levels of evidence6) that investigated the
effectiveness of LITUS.
• The literature search produced 3 possible studies related to
the clinical question: 2 randomized controlled trials and
1 case series met the inclusion and exclusion criteria2–4
(Figure 1).
• Based on the design of the included studies, the modified
Downs and Black checklist was used to critically appraise
the methodological quality of each study.7 Two independent
reviewers appraised each study and a consensus score was
reached to determine the methodological quality. Studies with
a score of ≥11/17 were considered high methodological
quality.
• Of the included studies, 1 study investigated the effects of
LITUS on tissue temperature,4 2 studies investigated the
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effects of LITUS on pain,2,3 and 1 study investigated LITUS
effects on function.2
• All included studies2–4 had positive effects for the measured
outcomes.
Clinical Bottom Line
The evidence supports the use of the LITUS unit to increase tissue
temperature,4 decrease pain,2,3 and increase function.2 Therefore,
practitioners may consider the use of the LITUS unit in patient popu-
lations over the use of the traditional high-intensity US treatment.
Strength of Recommendation
In accordance with the 2009 Centre for Evidence-Based Medicine
levels of evidence, there is grade I (insufficient) evidence to support
the positive effects of the LITUS device for improving the follow-
ing clinical outcomes: tissue temperature,4 decreasing pain,2,3 and
increasing function.2 The inconsistency in the measured outcomes
across the 3 studies only allows for minimal support of the LITUS
device; therefore, more research must be conducted. Although
clinical outcomes were different in each study, consistent evidence
ranging from 4 to 1B levels was found in the 3 included studies
(Figure 2).2–4
Search Strategy
Terms Used to Guide Search Strategy
• Patient: Nonapplicable













Studies retrieved and screened after duplicates 
removed
Relevant studies assessed
Studies included in analysis
Studies excluded due to nonhuman subjects
Studies excluded based on relevance and
investigating other types of ultrasound
Boolean phrases: low-intensity therapeutic ultrasound
a
Studies excluded due to lack of measurable 
outcomes, pilot studies, and case studies
Figure 1 — Database search results.
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Databases searched: 
(Academic Search Complete, Health 
Nursing/ Academic dition, CINAHL, MEDLINE 
















• Additional resources obtained via review of reference list and
hand search.
Inclusion and Exclusion Criteria
(Including Search Limits)
Inclusion
• Limited to English language studies
• Limited to level 4 evidence or higher
• Limited to the last 5 years (2012–2016)
• Limited to human subjects
• Prospective studies investigating and measuring outcomes of
the LITUS device
Exclusion
• Studies with no formal article publications (eg, pilot studies,
technical reports about the device)
Results of Search
Three relevant studies2–4 were identified and categorized as shown
in Table 1 (based on Levels of Evidence, Oxford Centre for
Evidence-Based Medicine, 2009).
Best Evidence
The studies in Table 2 were identified as the best evidence and
selected for inclusion in this critically appraised topic. These
studies were selected because they were graded with a level of
evidence of 4 or higher and examined the effects of LITUS
on clinical outcomes (tissue temperature, pain, and patient
function).
Implications for Practice, Education,
and Future Research
All 3 studies2–4 appraised in this critically appraised topic identified
positive results after use of a LITUS unit. Two studies3,4 were
categorized as high-quality evidence (1B) due to the fact that they
were randomized control trials, both receiving a score of 10/17 on
the modified Downs and Black checklist.7 Sources of bias included
lack of blinding of the therapists administering the therapy as well
as assessors measuring the temperature at different time points.
Although the Best et al2 study had the highest quality appraisal
score (15/17),7 it was level 4 evidence due to the nature of the case-
series study design. The findings of this appraisal indicate that there
is moderate-quality evidence to suggest that treatment from a
wearable LITUS unit increases tissue temperature, decreases
pain, and increases function.
Although the findings were consistent, the studies had
notable differences. Both Rigby et al4 and Lewis et al3 enrolled
patients who were randomly assigned to a treatment or placebo
(control) group. Participants were blinded to which group
they were in, and both studies had a 100% completion rate with
no adverse reactions reported. Best et al2 had no control group in
their study and their participants were recruited based on having
one of the 2 conditions: Achilles or elbow tendinopathy. All of the
patients received the intervention, and only 16 of the initial 25
enrolled completed the full 6-week protocol.2 Having such a
high dropout rate reduced the already small sample size, decreasing
the external validity of the study as well as limiting the generaliz-
ability of the results to people with only Achilles or elbow
tendinopathies.
Additional variation in the studies included each study having
a different implementation of their chosen intervention. Rigby
et al4 had participants attend 2 test sessions separated by 48 hours,
during which all data collection was completed. Lewis et al3
conducted 1-hour treatment sessions for 10 consecutive days,
while Best et al2 enrolled participants in a 6-week protocol with
treatment 4 hours per day at least 5 times per week. Implementing
each intervention in a different way eliminates continuity of the
studies, and makes it impossible to compare interventions and
results across studies. This allows for us to examine each study
individually for effectiveness of intervention, but disallows an
overall generalization of the results to be made.
In addition to the different enrollment methods, the included
studies had different outcome measures as well. Rigby et al4
assessed tissue temperature of the triceps surae muscle using
microprobe thermocouples. The Food and Drug Administration-








1 Rigby et al4
1B Randomized
control trial
1 Lewis et al3
4 Case series 1 Best et al2
Figure 2 — Wearable LITUS device (sam®; ZetrOZ Inc, Trumbull,
CT, USA).
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Table 2 Characteristics of Included Studies
Rigby et al4 Lewis et al3 Best et al2
Study design Repeated-measures cross-over design Randomized control trial Case series
Participants A total of 26 healthy participants [16 men
and 10 women, age = 23.0 (2.1) y]
enrolled and completed the study.
Exclusion criteria: subjects presenting with
fever, lower leg infection, or open wound;
compromised circulation or sensation;
injury to the lower leg within the 2 mo
before study or contraindication to US.
Groups were unbalanced intentionally to
assess intramuscular temperature changes
produced by the LITUS device while
controlling possible environmental
variables with a placebo group.
A total of 30 patients were recruited and
randomly assigned to the placebo (n = 10)
and active (n = 20) conditions.
Active group: n = 10 males and n = 10
females; placebo group: n = 1 male and
n = 9 females.
Inclusion criteria: age = 40–60 y; not be
pregnant; willing and able to self-
administer Tx daily; physician clearance;
agreement to record any reduction or
increase in prescription drug use in daily
diary; VAS scores of 4–7.
Exclusion criteria: neuropathy;
pregnancy; prisoners; surgery in the target
area within the last 6 mo; nonambulatory;
increasing use or initiate new use of meds
during the study; used topical agents other
than the US gel provided; clinically
significant or unstable medical or
psychological condition; participated in a
clinical trial for an investigational drug
and/or agent within 30 d before screening;
injury-related litigation in the target area;
clinically significant abnormal neurologic
Hx or examination at screening; back
spasms related to major trauma or
work-related injury; other severe pain that
may have confounded assessment or
self-evaluation of the trapezius myalgia.
A total of 25 participants with Achilles
[n = 5, age = 61.6 (8.0) y] or elbow
[n = 20, age 46.9 (9.6) y] tendinopathy
were enrolled.
Inclusion criteria: age = 18–65 y; able to
shave/remove hair in the area where the
applicator of the device will be applied;
access to a mobile phone or camera to take
a picture of the treatment site after use of
device; BMI ≤ 30.0; no NSAIDs treatment
or prescription pain meds at enrollment,
and agree to document all pain meds used
during the study period.
Exclusion criteria: Hx or current Dx of a
tendon tear; known neuropathy; prisoners;
smokers; type 1 or type 2 diabetes; surgery
in target Tx area within the last 6 mo;
nonambulatory; pacemaker; other
malignancy; use of pain meds during the
trial unless medically necessary to ensure
safety; use of topical agents other than the
US gel provided; refuse to discontinue all
other interventional treatment modalities;
underwent a local corticosteroid or
platelet-rich plasma injection within the
past 3 mo; medical or psychological
condition that would compromise
participation; participated in a clinical trial
for an investigational drug and/or agent
within 30 d prior to screening; involved in
any injury-related litigation; open sores




Participants attended 2 test sessions
separated by 48 h for Tx with the LITUS
device (model sam-12; ZetrOZ Inc).
During first visit, the participants received
Tx with either one 7000 J or 14,000 J
US transducer, and alternate Tx
administered at second testing session.
Parameters were set to 3-MHz frequency
and 0.132W/cm2 spatial average temporal
average intensity for 3 h.
Tx occurred at the same time of the day to
limit diurnal variation. Participants in the
placebo group received the placebo Tx for
both sessions. LITUS devices were
configured and applied. Devices were
clipped to a medical tape bandage and US
gel was used as coupling agent. For single-
transducer Tx, devices were equally
spaced above previously placed
temperature probes within the tissue; for
dual-transducer treatments, devices were
spaced above the temperature probes.
Participants were then instructed to lie still
for remainder of treatment (180 min)
FDA status of the device was not clearly
stated by authors.
Participants participated in at least ten 1-h
US Tx sessions at the onset of heightened
pain caused by trapezium spasm. Tx
parameters were not identified by authors,
but the LITUS device works at 2.5–3MHz
with 0.03–2W/cm2 intensity capability for
0.3–18 h of treatment, depending on the
output setting.
Sessions lasted 1 h/d for continuous 10 d;
participants were instructed to record their
pain level every 15 min during duration
of Tx. Participants were instructed how
to properly apply and utilize the LITUS
device, and then given individual
participant kit, which included the LITUS
device with a belt clip, three 2-oz US
coupling gel packets, twenty 10 × 10.5-cm
adhesive bandages, a system wall charger,
a user manual, and a patient diary for
self-reporting. Majority of the participants
completed the study from their home or
work environment, minimizing the impact
the device had on their lifestyle.
LITUS device manufacturer information
was not provided, but the electronics and
battery pack were integrated into a
commercially available housing (OKW,
Bridgeville, PA). FDA status of the device
was not clearly stated by authors.
Subjects recruited from 3 clinics and
compensated up to $150 based on the
number of completed study visits. Three
subjects withdrew from study. Twenty-
one participants completed the first
follow-up visit at 2 wk, 18 completed
4 wk, and 16 completed the full 6-wk
protocol.
All subjects reported to the clinic initial
screening and enrollment visit. Subjects
taught to apply the LITUS device (sam®;
ZetrOZ Inc, cleared by FDA in Nov 2013)
and instructed to apply it to their affected
tendon for 4-h treatment sessions at least
5 times per wk for 6 wk. Parameters of
US Tx were 3-MHz frequency and
0.132 W/cm2 intensity per applicator,
continuous wave form, BNR: <5:1, ERA:
6 cm2 (per applicator) for up to 4 h per
treatment session.
Subjects returned to the clinic for
assessments of safety and efficacy at the
end of 2, 4, and 6 wk of Tx, and
maintained a diary of Tx and symptoms at
home throughout the 6-wk period. Each
subject wore 1 applicator directly over the
tendon (Achilles or medial/lateral elbow)
and another just upstream of it using a
Y-adaptor connected to the power
controller.
(continued)
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approved LITUS device (model sam-12; ZetrOZ Inc, Trumbull,
CT) was set to a frequency of 3 MHz and an intensity of 0.132 W/
cm2 for a total of 3 hours.4 Temperature was measured 5 minutes
prior to the treatment and for 30 minutes after the 3-hour treatment
session. Temperatures were taken in degree Celsius, and average
temperature increases between 3°C and 4°C were found for each
treatment condition when compared with the control group. These
increases (3°C–4°C) are very similar to temperature increases
achieved by traditional US units.3
Lewis et al3 assessed pain in patients with chronic trapezius
myalgia using 3 different outcome measures: the Visual Analog
Scale Score, global rating of change, and annotated pain diagrams.
Visual Analog Scale Score results among all patients were positive,
with the majority of patients reporting the greatest reduction in pain
during the first 3–4 days. On average, placebo users had an 8% pain
reduction; female active users had a 12% pain reduction, and male
active users had a 19% pain reduction. The average global rating of
change score in the test group reported improvements 60% greater
than that reported in the placebo group. Findings suggest that the
LITUS unit is effective at reducing chronic trapezius myalgia while
producing no reports of negative side effects. However, the major-
ity of participants were previously using a prescribed method of
pain control and they were not asked to stop taking their medication
while participating in the study, making it difficult to determine
whether the results were due to the LITUS unit, the pain medica-
tions, or a combination of the 2 interventions.
Best et al2 measured pain and function of participants with
either chronic elbow or chronic Achilles pathology initially, and at
Table 2 (continued)
Rigby et al4 Lewis et al3 Best et al2
Outcome
measures
Tissue temperature was assessed using
microprobe thermocouple (MT 23/5;
Physitemp Instruments LLC, Clifton, NJ).
Two PT-6 thermocouples (Physitemp
Instruments LLC) were used to assess skin
surface and ambient temperature. Initial
tissue temperature was measured 5 min
before the 180-min LITUS treatment, and
posttreatment temperature was recorded
for 30 min.
Outcomes were measured using 3 tools:
VAS, GROC, and annotated pain
diagrams. Patients reported pain before
and after Tx.
Pain ratings were recorded using a
standardized 11-point numeric rating
scale. Subjects self-reported pain 4 times
per day during 6-wk Tx: before Tx, 30min
into Tx, 2 h into Tx, and at conclusion of
the Tx. Subjects rated their pain using the
numeric rating scale providing a rating for
the worst and best levels of pain for the
previous week and current level of pain.
Force generation and grip strength were
assessed at each study visit via a handheld
dynamometer for elbow pathology and




Increase in tissue temperature was
observed in the active US group: at 1.5-cm
depth, tissue temperatures increased
4.45°C (1.52°C) from 1 transducer and
3.95°C (1.10°C) from 2 transducers. At
3-cm depth, tissue temperature increased
3.18°C (0.90°C) from 1 transducer and
3.22°C (0.95°C) from 2 transducers
Therapeutic temperature change (>1°C)
was maintained for approximately 3 h.
Mild heating (>1°C) was reached at 10 (5)
min and vigorous heating (>4°C) was
reached at 80 (10) min. A difference was
noted between final normalized IM
temperature measured at each depth
(t78 = 2.45, P = .02), but the number of
transducers used to generate heating was
not different (t78 = 1.79, P = .08).
Patients successfully reported with all
3 measures. VAS results among patients
were positive with the greatest pain
reduction reported during the first 3–4 d.
Pain reduction was 8% for placebo user,
12% for active female users, and 19%
for active male users. Across the 10 Tx
sessions, GROC scores showed
improvement 60% greater than the
placebo group. Active female patients
reported no statistically significant or
trending effects, whereas the placebo
group on average reported upper back pain
after 60 min of Tx. Active men reported a
30% pain reduction over placebo. Active
male and female patients responded to
treatment faster than the placebo group.
Post-60-min LITUS Tx, placebo and
active male groups reported increased
pain, while active females reported a
continued decrease in pain after
conclusion of the treatment.
Of the subjects who completed the full
6-wk protocol, 62.5% experienced at least
a 50% decrease in pain, and on average
had a 3.94 (2.15) point decrease from
baseline. At the beginning of the
experiment, grip strength was 26.88 (9.89)
kg force in the injured arm and 33.49
(11.15) kg force in the uninjured arm. Grip
strength increased by 2.83 (5.52) kg force
between baseline and week 2 in the
injured arm. No significant increases in
strength in the untreated arm. On average,
there was improvement in exerted force
measured by dynamometer of the affected
leg with treatment in the Achilles group.
Statistical analyses on the pain and
strength data were not performed due to




Validity score Modified Downs and Black Score 10/17 Modified Downs and Black Score 10/17 Modified Downs and Black Score 15/17
Conclusion The LITUS device heated tissues at 1.5
and 3.0 cm deep by approximately
3°C–4°C.
The LITUS device in conjunction with
pain management medication is effective
at reducing patients’ chronic trapezius
myalgia while producing no reports of
negative side effects.
Sustained acoustic medicine may be an
effective therapy for elbow and Achilles
tendinopathy. Results provide evidence
that the LITUS device safely treats tendon
injuries.
Abbreviations: BNR, beam nonuniformity ratio; BMI, body mass index; Dx, diagnosis; ERA, effective radiating area; FDA, Food and Drug Administration; GROC, global
rating of change; Hx, history; LITUS, low-intensity therapeutic ultrasound; IM, intramuscular; NSAID, nonsteroidal anti-inflammatory drug; Tx, treatment; US, ultrasound;
VAS, Visual Analog Scale Score.
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the end of 2, 4, and 6 weeks of treatment. Pain was measured using
a standardized, 11-point numeric rating scale: 0 (no pain) and 10
(extreme pain). Function was measured by taking musculotendi-
nous force generation assessments at each visit. Elbow pathology
subjects measured grip strength with a handheld dynamometer,
while Achilles pathology subjects used a MicroFET dynamometer
(Hoggan Scientific LLC, Salt Lake City, UT). Of the subjects in the
elbow tendinopathy group who completed the full 6-week protocol,
62.5% experienced at least a 50% decrease in pain. Grip strength
increased by 2.83 (5.52) kg force between baseline and week 2 in
the injured arm. On average, there was an improvement in exerted
force measured by the dynamometer of the affected leg with
treatment in the Achilles group. Results suggest that sustained
acoustic medicine may be an effective therapy for elbow and
Achilles tendinopathy.
To date, there are the only 3 studies2–4 to investigate the effects
of the LITUS unit on measurable outcomes. This portable light-
weight unit has produced increased tissue temperatures and pain
relief comparable with the effects achieved by traditional high-
intensity, short-duration therapeutic US.3 The battery pack of the
LITUS unit is small enough to fit in your hand, and the transducers
attach easily to the skin for the duration of the treatment session.
Furthermore, the treatment process is simple enough that patients
can be instructed by clinicians on application during their first
usage, and should be able to apply and treat themselves for the
remaining duration of their treatment sessions. This allows clin-
icians to spend their time working with other patients, as well as
allowing the patient the ability to carry out their activities of daily
living while wearing the unit. In addition, patients will be able to
self-administer treatments as they deem necessary, eliminating the
need for multiple scheduled appointments with their clinicians just
for treatment.
Future research is needed to examine the long-term effects of
the LITUS unit, and to establish any true differences between the
portable LITUS unit and a traditional high-intensity, short-duration
US unit. Conducting future studies over time may demonstrate how
the long-duration, low-intensity acoustic energy affects different
tissues, as well as tissue degradation rates when compared with
those seen with traditional US. Identifying the influence of the
LITUS unit on different measures of self-reported function
(regional, global, and mental) may also provide valuable informa-
tion to support the use of the wearable LITUS unit. Finally,
designing future studies using good-quality randomized controlled
trials will help provide higher-level evidence to support the use of a
wearable LITUS unit. This critically appraised topic should be
reviewed in 2 years to determine whether there is additional best
evidence that may change the clinical bottom line for this clinical
question.
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